

The Immune Response Corporation (Carlsbad, CA) has appointed **John N. Bonfiglio** as chief executive officer. He was most recently chief operating officer and executive vice president at Cypress Biosciences.

Nanosys (Palo Alto, CA) has announced the addition of **Louis Brus**, professor of chemistry at Columbia University, as a scientific advisor to the company. Dr. Brus, one of the earliest contributors to the field of nanotechnology, was responsible for discovering the "quantum dot" and explaining the fundamental physics of quantum size-effects in semiconductor nanocrystals.

Neurochem (Montreal, PQ, Canada) has appointed **Philippe Calais** as president. Dr. Calais most recently served as general manager of Servier Canada, and was previously global business leader for anti-infectives at Hoffmann-La Roche.

**Barry I. Eisenstein** has been appointed executive vice president, R&D, and **David H. Schubert** has been named vice president, regulatory affairs, and quality assurance at Cubist Pharmaceuticals (Lexington, MA). Dr. Eisenstein joins Cubist from ActivBiotics, where he served as president, chief scientific and medical officer, and board member, as well as vice president, science and technology at Beth Israel Deaconess Medical Center. Mr. Schubert most recently served as vice president of regulatory affairs and quality assurance at Zycos.

**Robert A. Ingram** has been elected chairman of the board of directors of OSI Pharmaceuticals (Melville, NY). Mr. Ingram recently retired as chief operating officer and president of pharmaceutical operations at GlaxoSmithKline, and is the current vice chairman, pharmaceuticals at GSK.

BioXcell SpA (Milan, Italy) has announced the appointment of **Alex Martin** as chief business officer and a member of BioXcell's executive committee. Mr. Martin most recently served as vice president, global business development and licensing at Novartis Pharma.

**G. Kelly Martin** has been named president and CEO of Elan (Dublin, Ireland). He will also join the company's board of directors. Most recently, Mr. Martin was a member of both the executive management and operating committee of Merrill Lynch & Co. and was formerly president of its international private client group.

Wilson Sonsini Goodrich & Rosati (Palo Alto, CA) has announced the addition of

**Vern Norviel** as partner. Mr. Norviel joins the firm from Perlegen Sciences, where he served as general counsel and corporate secretary. Prior to Perlegen, he was senior vice president and general counsel at Affymetrix.

Privately held Aton Pharma (Tarrytown, NY) has announced the appointment of **Dennis J. Purcell** to its board of directors. Mr. Purcell is senior managing partner of the Perseus-Soros Biopharmaceutical Fund, which recently participated in the company's recent round of equity financing.

**Peter Ringrose** has been named non-executive director to the board of Cambridge Antibody Technology (Cambridge, UK). Dr. Ringrose was most recently chief scientific officer and president of the Bristol-Myers Squibb Research Institute, and a member of the executive committee of Bristol-Myers Squibb Company. He retired from these roles in December 2002. Prior to joining BMS, he was senior vice president, worldwide drug discovery and European medicinal R&D at Pfizer.

Dendreon (Seattle, WA) has named **Israel Rios** vice president of clinical affairs. Dr. Rios joins the company after spending a decade at Berlex Laboratories, where he most recently served as vice president of oncology development.

**Whaijen Soo** has been appointed senior vice president, medical research at Biogen (Cambridge, MA). He joins the company after 17 years at Roche, where he most recently served as vice president, clinical sciences. In addition, Biogen has announced that **Bob Hamm** has been appointed senior vice president of North American commercial operations, a newly created position. Mr. Hamm joined Biogen in 1994 as associate director, logistics.



Pyrosequencing (Uppsala, Sweden) has named **Mats-Olof Wallin** as chief financial officer, effective March 2003. Mr. Wallin, currently chief financial officer at Ortivus, previously held leading positions in various financial functions in the Pharmacia Group.

**Michael Weiss** has been appointed chairman and chief executive officer of Keryx (Jerusalem, Israel), replacing **Benjamin Corn**, who is resigning as president and CEO, and **Morris Laster**, who is resigning as chairman. Mr. Weiss is the vice chairman of Genta.